Methio-Form ® Chewable Tablets (DL-methionine)

Manufacturer
LLOYD, Inc. of Iowa | Sumitomo Chemical Company, Limited
Effective date
2014-08-21
Label type
PRESCRIPTION ANIMAL DRUG LABEL
Version
2
Source
legacy-cache
Hydrated at
2026-08-02 01:35:23

Label at a glance#

ProductMethio-Form
Active ingredientRACEMETHIONINE
Label structure14 sections

Indications and uses

For use as an aid in acidifying the urine of dogs and cats. Methio-Form is also an aid in controlling the odor from feline and canine urine residues. Methio-Form Chewable Tablets may be used as a source of the essential amino acid, DL-methionine.

Storage and handling

Store at room temperature and protect from light. Avoid excessive heat (104°F).

Label contents#

Full prescribing information#

Caution

SAFE HANDLING WARNING SECTION

U.S. Federal Law restricts this drug to use by or on the order of a licensed veterinarian.

Indications and Usage

INDICATIONS & USAGE SECTION

For use as an aid in acidifying the urine of dogs and cats. Methio-Form is also an aid in controlling the odor from feline and canine urine residues.

Methio-Form Chewable Tablets may be used as a source of the essential amino acid, DL-methionine.

Description

DESCRIPTION SECTION

Each scored Methio-Form Chewable Tablet contains 500 mg DL-methionine (6.7 milliequivalents [mEq]) in a palatable protein base.

Clinical Pharmacology

CLINICAL PHARMACOLOGY SECTION

DL-methionine [2 amino-4-(methyl-thio)butyric acid], a sulfur-containing essential amino acid,1,2 is soluble in water and dilute acid, but is insoluble in most organic solvents. The pH of a 1% solution is 5.6 to 6.0. It has been established that methionine is the source of approximately 80% of the sulfur in cystine, one of the most important amino acids in mammalian metabolism3. The role of methionine in the formation of choline and creatinine is well known.3 Methionine ingested in excess of normal metabolic needs for the amino acid may be metabolized in many ways. A simplified diagram of the catabolism of methionine in the mammalian liver is presented below, and illustrates why DL-methionine may be an effective, continuous urinary acidifying agent4. One millimole of methionine (149.2 mg) as it is metabolized in the liver will theoretically produce 2 mEq of sulfuric acid, which is excreted largely in the urine.

Chemical StructureChemical Structure

Methio-Form may be used to prevent the formation of magnesium ammonium phosphate hexahydrate (MgNH4PO4• 6H2O) crystals in the urine. These crystals are commonly called struvite. Struvite is the most frequently involved mineral in uroliths that occur in feline lower urinary tract disease (LUTD) also known as feline urologic syndrome (FUS). Struvite crystals are more soluble in acid urine and tend not to develop and will eventually dissolve as urinary pH is reduced.

Methionine is effective in increasing titratable acidity6, a measure of buffering capacity on the ability to neutralize acids and bases. Methionine can be expected to decrease pH from control values (pH) approximately 0.80 pH units at a daily dose of 5 mEq(375mg)/kg body weight (Figure 1). This same dose has increased titratable acidity 42.4 mEq/liter of urine. (Figure 2).

Figure 1. Change in Feline urinary pH after administration of Methio-Form.

Figure 1
Figure 1

Figure 2. Change in Feline urine Titratable Acidity after administration of Methio-Form.

Figure 2
Figure 2

Urinary pH is primarily a function of diet, with proteins routinely decreasing pH and minerals generally increasing pH. The diets of cats and dogs may be expected to produce urine pH values of 6.6 to 7.2. Therefore, a dose of 5 mEq (375 mg) of methionine/kg body weight should effect a urinary pH value of 5.8 to 6.2. Daily administration is necessary to maintain continuous effects in pH and TA. Adaptation does not occur, but approximately 2 days of dosing is required to attain the maximum effects (Figure 3)6.

LUTD (FUS) is relatively common and affects both sexes; however, male cats are more frequently involved. Cystitis and urolithiasis produce post-renal uremia with elevated blood urea nitrogen (BUN), hyperphosphatemia, hyperkalemia, metabolic acidosis, and death if not treated.

The following principles have been suggested for uroliths in LUTD that are predominantly composed of struvite to reduce the concentration of pre-struvite crystalloids and formation of calculi:

  1. Reducing crystalloid concentration by reducing dietary concentration of magnesium and phosphorus to minimal requirements.
  2. Increasing urinary volume by increasing water intake.
  3. Increasing solubility of crystalloids by reducing urinary pH and holding at a reduced value7.

Methio-Form Chewable Tablets, are designed to furnish a convenient, effective and practical dosage form for urinary acidification. They reduce the client compliance problem of daily administration of conventional tablets. Methio-Form Chewable Tablets are highly palatable to cats and dogs.

Figure 3. Time-related effects of methionine on Feline urinary pH

Figure 3Figure 3

Contraindications

CONTRAINDICATIONS SECTION

Do not administer to animals with severe liver, kidney or pancreatic disease, or those which are acidotic due to conditions such as uncontrolled diabetes mellitus or urinary obstruction.

Warning

WARNINGS SECTION

Methio-Form is extremely palatable to dogs and cats and overconsumption of tablets may result if access to open bottles occurs. The effect of overconsumption may be severe and could result in life-threatening metabolic acidosis if veterinary treatment is not initiated.

Also, excess consumption of methionine may result in the production of methyl mercaptan (methanethiol) which may be toxic. In animals with healthy livers, metabolites of methionine are converted to nontoxic substances. Generally, methionine in the diet at twice the required level is well tolerated, but at a threefold or above level toxicosis often results.

Precautions

PRECAUTIONS SECTION

In rare cases animals may experience gastrointestinal disturbance. In those cases, administer during feeding or in two to three divided doses.

Caution should be advised against overdosing animals to avoid chronic over acidification which could lead to potential problems such as acidosis, potassium wasting, osteoporosis, Heinz body formation, and possible precipitation of non-struvite minerals in the urine.

Cats have been frequently poisoned by ingesting numerous tablets from bottles which were left open. The intoxication resulting from accidental over consumption is primarily an acidemia. Cats which are presented for treatment within 4 hours after a substantial over consumption event will benefit from emptying the stomach by use of emetics or gavage. Activated charcoal (ToxiBan™, Vet-A-Mix) will be helpful if administered in oral doses of one to two g/kg body weight with or without gavage and before cats become severely intoxicated with signs of ataxia, depression and coma. The recommended treatments for the acidosis include parenteral solutions, such as saline-bicarbonate with dextrose, lactated Ringer, lactate, bicarbonate, or Darrow's or Butler's for acidosis. Sodium bicarbonate administered orally may be helpful unless the animal has been vomiting frequently. Avoid the use of ammonium salts of solutions. Adult cats ingesting 20 Methio-Form tablets at one time may be expected to become nonlethally intoxicated, but cats ingesting 40 or more tablets will probably die without treatment.

Administration

DOSAGE & ADMINISTRATION SECTION

Methio-Form Chewable Tablets may be fed free choice, from the hand or may be crumbled and mixed into the food. Dosing one time each day is appropriate, but daily doses may be administered in 2 or 3 divided doses if more convenient or in rare cases where animals may vomit a single daily dose.

For urinary acidification in cats and dogs and prevention of struvite urolithiasis urinary pH should be reduced to approximately 6.0 - 6.6 and maintained in this range. Monitoring the pH of freshly voided urine may be advisable.

Dosage

DOSAGE FORMS & STRENGTHS SECTION

Daily dosages vary with diets and amount of acidification needed. After dosages have been determined, they may be used continuously.

Cats

SPL UNCLASSIFIED SECTION

The usual daily dose is 2.5 to 5.0 mEq (188-375 mg)/kg body weight or ½ to one tablet per 1 to 1.5 kg. (2.5 to 3 lb) body weight. Average size adult cats normally should receive 1½ to 3 tablets (10-20 mEq) daily.

Dogs

SPL UNCLASSIFIED SECTION

The usual daily dose is 2 to 4 mEq (150-300 mg)/kg body weight. Small breeds - 7 kg (15 lb) or under, ½ to 4 tablets. Medium Breeds - 7 to 15 kg (15-33 lb), 2 to 7 tablets. Large Breeds - 15-30 kg (33-66 lb), 4 to 13 tablets.

Note: Methio-Form tablets can be crumbled and sprinkled on the animal's food. A level teaspoonful of a crumbled tablet contains 746 mg (10.0 mEq) of DL-methionine.

Storage

STORAGE AND HANDLING SECTION

Store at room temperature and protect from light. Avoid excessive heat (104°F).

How Supplied

HOW SUPPLIED SECTION

50 tablet bottlesList No. 2403
150 tablet bottlesList No. 2404
500 tablet bottlesList No. 2402

Patent Pending

Bibliography

REFERENCES SECTION

  1. Nutrient Requirements of Cats, Rev. 1986, National Research Council, National Academy of Sciences, page 11.
  2. Nutrient Requirements of Dogs, Rev. 1985, National Research Council, National Academy of Sciences, page 11.
  3. Osol, Arthur and Farrar, George: The Dispensatory of the United States of America, 25th ed., 1960, J. B. Lippincott Co., Philadelphia, PA, page 850.
  4. Bell, George; Davidson, J., and Scarborough, Harold: Textbook of Physiology and Biochemistry, ed. 6, 1965, The Williams and Wilkins Company, Baltimore, MD, pages 364 and 365.
  5. Goodman, L. and Gilman, A: The Pharmacological Basis of Therapeutics, ed. 8, 1980, Pergamon Press, NY, page 697.
  6. Lloyd, WE; Sullivan, DJ: Effects of orally administered ammonium chloride and methionine on feline urinary acidity, VM/SAC 79: 773-778, 1984.
  7. Osborne, CA; Lees, GE: Feline Cystitis, Urethritis, Urethral Obstruction Syndrome, Mod Vet Pract59:513-518, 1978.

SPL UNCLASSIFIED SECTION

Manufactured by
LLOYD, Inc
Shenandoah, IA 51601 USA

Rev. 1110

PRINCIPAL DISPLAY PANEL - 500 Tablet Bottle Label

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

DIN 00422193

Methio-Form®
(DL-Methionine)
Chewable Tablets

Indications: For use as an aid in acidifying the urine of
cats and dogs

Caution: Federal law restricts this drug to use by or on the
order of a licensed veterinarian.

LLOYD

500 Tablets

PRINCIPAL DISPLAY PANEL - 500 Tablet Bottle Label
PRINCIPAL DISPLAY PANEL - 500 Tablet Bottle Label

DailyMed Socrata Ingredients#

Ingredient, Type, UNII table
IngredientTypeUNIISPL versionUploaded
RACEMETHIONINEACTIVE INGREDIENT73JWT2K6T32
RACEMETHIONINEACTIVE MOIETY73JWT2K6T32
ACACIAINACTIVE INGREDIENT5C5403N26O2
BUTYLATED HYDROXYANISOLEINACTIVE INGREDIENTREK4960K2U2
BUTYLATED HYDROXYTOLUENEINACTIVE INGREDIENT1P9D0Z171K2
CELLULOSE, MICROCRYSTALLINEINACTIVE INGREDIENTOP1R32D61U2
CITRIC ACID MONOHYDRATEINACTIVE INGREDIENT2968PHW8QP2
COD LIVER OILINACTIVE INGREDIENTBBL281NWFG2
CORN OILINACTIVE INGREDIENT8470G57WFM2
ETHOXYQUININACTIVE INGREDIENT9T1410R4OR2
FD&C BLUE NO. 1INACTIVE INGREDIENTH3R47K3TBD2
FD&C RED NO. 40INACTIVE INGREDIENTWZB9127XOA2
FD&C YELLOW NO. 6INACTIVE INGREDIENTH77VEI93A82
GLYCERININACTIVE INGREDIENTPDC6A3C0OX2
LACTOSEINACTIVE INGREDIENTJ2B2A4N98G2
LACTOSE MONOHYDRATEINACTIVE INGREDIENTEWQ57Q8I5X2
MAGNESIUM STEARATEINACTIVE INGREDIENT70097M6I302
METHYLCELLULOSE (400 MPA.S)INACTIVE INGREDIENTO0GN6F9B2Y2
POVIDONE K29/32INACTIVE INGREDIENT390RMW2PEQ2
PROPYLENE GLYCOLINACTIVE INGREDIENT6DC9Q167V32
SILICON DIOXIDEINACTIVE INGREDIENTETJ7Z6XBU42
SODIUM BENZOATEINACTIVE INGREDIENTOJ245FE5EU2
SODIUM CHLORIDEINACTIVE INGREDIENT451W47IQ8X2
SODIUM LAURYL SULFATEINACTIVE INGREDIENT368GB5141J2
SOYBEANINACTIVE INGREDIENTL7HT8F1ZOD2
SOYBEAN OILINACTIVE INGREDIENT241ATL177A2
STARCH, CORNINACTIVE INGREDIENTO8232NY3SJ2
WATERINACTIVE INGREDIENT059QF0KO0R2
YEASTINACTIVE INGREDIENT3NY3SM6B8U2

Products#

Every source-derived product name is available through these pages.

DailyMed product names page 1 of 1 · 29 matching rows.

NDC Codes#

Product NDC, Package NDC table
Product NDCPackage NDC
11789-24011789-240-30, 11789-240-40, 11789-240-20

Ingredients#

Every source-derived ingredient row is available through these pages.

DailyMed ingredient rows page 1 of 1 · 28 matching rows.

Source Document#

Source XML

Inactive ingredient matches#

Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.

Inactive ingredient links page 1 of 15 · 864 matching rows.

DailyMed ingredient, IID ingredient, UNII table
DailyMed ingredientIID ingredientUNIIDosage form / routePotencyMaximum daily exposureMatch
CITRIC ACID MONOHYDRATECITRIC ACID MONOHYDRATE2968PHW8QPLIQUID / RESPIRATORY (INHALATION)0.13 %w/wExact identifier — unii candidate
88 equally ranked IID candidates
SODIUM CHLORIDESODIUM CHLORIDE451W47IQ8XINJECTION, SUSPENSION / INTRA-ARTICULAR26 mgExact identifier — unii candidate
134 equally ranked IID candidates
SODIUM LAURYL SULFATESODIUM LAURYL SULFATE368GB5141JCAPSULE, COATED, EXTENDED RELEASE / ORALNAExact identifier — unii candidate
42 equally ranked IID candidates
CITRIC ACID MONOHYDRATECITRIC ACID MONOHYDRATE2968PHW8QPCREAM / VAGINAL0.49 %w/wExact identifier — unii candidate
88 equally ranked IID candidates
PROPYLENE GLYCOLPROPYLENE GLYCOL6DC9Q167V3LOTION, AUGMENTED / TOPICAL2070 mgExact identifier — unii candidate
81 equally ranked IID candidates
GLYCERINGLYCERINPDC6A3C0OXJELLY / TOPICALNAExact identifier — unii candidate
75 equally ranked IID candidates
GLYCERINGLYCERINPDC6A3C0OXSYRUP / ORAL16734 mgExact identifier — unii candidate
75 equally ranked IID candidates
PROPYLENE GLYCOLPROPYLENE GLYCOL6DC9Q167V3SOLUTION/ DROPS / AURICULAR (OTIC)ADJ PHExact identifier — unii candidate
81 equally ranked IID candidates
LACTOSELACTOSEJ2B2A4N98GTABLET, EXTENDED RELEASE / ORAL400 mgExact identifier — unii candidate
36 equally ranked IID candidates
SODIUM BENZOATESODIUM BENZOATEOJ245FE5EUPOWDER, FOR SUSPENSION / ORAL160 mgExact identifier — unii candidate
35 equally ranked IID candidates
SODIUM CHLORIDESODIUM CHLORIDE451W47IQ8XSOLUTION / INTRAOCULAR320 mgExact identifier — unii candidate
134 equally ranked IID candidates
SODIUM LAURYL SULFATESODIUM LAURYL SULFATE368GB5141JGEL / DENTAL1.47 %w/wExact identifier — unii candidate
42 equally ranked IID candidates
GLYCERINGLYCERINPDC6A3C0OXSOAP / TOPICAL0.76 %w/wExact identifier — unii candidate
75 equally ranked IID candidates
SODIUM BENZOATESODIUM BENZOATEOJ245FE5EUENEMA / RECTAL60 mgExact identifier — unii candidate
35 equally ranked IID candidates
ACACIAACACIA5C5403N26OCAPSULE / ORAL20 mgExact identifier — unii candidate
19 equally ranked IID candidates
BUTYLATED HYDROXYANISOLEBUTYLATED HYDROXYANISOLEREK4960K2USOLUTION / ORAL5 mgExact identifier — unii candidate
24 equally ranked IID candidates
SODIUM LAURYL SULFATESODIUM LAURYL SULFATE368GB5141JCAPSULE, COATED PELLETS / ORAL1 mgExact identifier — unii candidate
42 equally ranked IID candidates
LACTOSELACTOSEJ2B2A4N98GTABLET, SUGAR COATED / ORALNAExact identifier — unii candidate
36 equally ranked IID candidates
STARCH, CORNSTARCH, CORNO8232NY3SJTABLET / ORAL1116 mgExact identifier — unii candidate
22 equally ranked IID candidates
FD&C BLUE NO. 1FD&C BLUE NO. 1H3R47K3TBDCAPSULE, COATED, EXTENDED RELEASE / ORALNAExact identifier — unii candidate
37 equally ranked IID candidates
GLYCERINGLYCERINPDC6A3C0OXOINTMENT / TOPICALNAExact identifier — unii candidate
75 equally ranked IID candidates
SILICON DIOXIDESILICON DIOXIDEETJ7Z6XBU4GEL / NASAL20 mgExact identifier — unii candidate
49 equally ranked IID candidates
CITRIC ACID MONOHYDRATECITRIC ACID MONOHYDRATE2968PHW8QPSOLUTION / INTRAVENOUS10 mgExact identifier — unii candidate
88 equally ranked IID candidates
FD&C BLUE NO. 1FD&C BLUE NO. 1H3R47K3TBDELIXIR / ORALNAExact identifier — unii candidate
37 equally ranked IID candidates
LACTOSELACTOSEJ2B2A4N98GSOLUTION / RECTAL8 %w/vExact identifier — unii candidate
36 equally ranked IID candidates
FD&C YELLOW NO. 6FD&C YELLOW NO. 6H77VEI93A8MOUTHWASH / BUCCAL0.01 mg/1mlExact identifier — unii candidate
34 equally ranked IID candidates
LACTOSELACTOSEJ2B2A4N98GTABLET / RECTAL20 mgExact identifier — unii candidate
36 equally ranked IID candidates
PROPYLENE GLYCOLPROPYLENE GLYCOL6DC9Q167V3SUSPENSION / AURICULAR (OTIC)10 %w/vExact identifier — unii candidate
81 equally ranked IID candidates
LACTOSE MONOHYDRATELACTOSE MONOHYDRATEEWQ57Q8I5XPOWDER / RESPIRATORY (INHALATION)25 mgExact identifier — unii candidate
38 equally ranked IID candidates
FD&C BLUE NO. 1FD&C BLUE NO. 1H3R47K3TBDSOLUTION / RECTAL0.01 %w/vExact identifier — unii candidate
37 equally ranked IID candidates
SODIUM BENZOATESODIUM BENZOATEOJ245FE5EUGEL / DENTAL0.08 %w/wExact identifier — unii candidate
35 equally ranked IID candidates
ACACIAACACIA5C5403N26OTABLET, FILM COATED / ORAL0.14 mgExact identifier — unii candidate
19 equally ranked IID candidates
SILICON DIOXIDESILICON DIOXIDEETJ7Z6XBU4GRANULE, FOR SOLUTION / ORAL1.8 mg/120mlExact identifier — unii candidate
49 equally ranked IID candidates
CITRIC ACID MONOHYDRATECITRIC ACID MONOHYDRATE2968PHW8QPINJECTION / INTRATHECALADJ PHExact identifier — unii candidate
88 equally ranked IID candidates
STARCH, CORNSTARCH, CORNO8232NY3SJTABLET, ORALLY DISINTEGRATING, DELAYED RELEASE / ORAL21 mgExact identifier — unii candidate
22 equally ranked IID candidates
SODIUM LAURYL SULFATESODIUM LAURYL SULFATE368GB5141JSPONGE / TOPICAL5 %w/wExact identifier — unii candidate
42 equally ranked IID candidates
MAGNESIUM STEARATEMAGNESIUM STEARATE70097M6I30LOZENGE / TRANSMUCOSAL100 mgExact identifier — unii candidate
39 equally ranked IID candidates
SOYBEAN OILSOYBEAN OIL241ATL177AINJECTION, POWDER, LYOPHILIZED, FOR SOLUTION / INTRAVENOUS10 %w/vExact identifier — unii candidate
7 equally ranked IID candidates
GLYCERINGLYCERINPDC6A3C0OXFILM, EXTENDED RELEASE / TRANSDERMAL306.2 mgExact identifier — unii candidate
75 equally ranked IID candidates
FD&C YELLOW NO. 6FD&C YELLOW NO. 6H77VEI93A8CAPSULE, LIQUID FILLED / ORAL1 mgExact identifier — unii candidate
34 equally ranked IID candidates
BUTYLATED HYDROXYANISOLEBUTYLATED HYDROXYANISOLEREK4960K2UINJECTION, POWDER, FOR SOLUTION / INTRAVENOUSNAExact identifier — unii candidate
24 equally ranked IID candidates
CELLULOSE, MICROCRYSTALLINEMICROCRYSTALLINE CELLULOSEOP1R32D61UCAPSULE, DELAYED RELEASE / ORAL366 mgExact identifier — unii candidate
28 equally ranked IID candidates
MAGNESIUM STEARATEMAGNESIUM STEARATE70097M6I30GRANULE, FOR SUSPENSION / ORAL14 mgExact identifier — unii candidate
39 equally ranked IID candidates
SODIUM CHLORIDESODIUM CHLORIDE451W47IQ8XTABLET, EXTENDED RELEASE / ORAL335.1 mgExact identifier — unii candidate
134 equally ranked IID candidates
CITRIC ACID MONOHYDRATECITRIC ACID MONOHYDRATE2968PHW8QPINJECTION / INTRASYNOVIALADJ PHExact identifier — unii candidate
88 equally ranked IID candidates
SODIUM CHLORIDESODIUM CHLORIDE451W47IQ8XSUSPENSION / SUBCUTANEOUS0.8 %w/vExact identifier — unii candidate
134 equally ranked IID candidates
BUTYLATED HYDROXYANISOLEBUTYLATED HYDROXYANISOLEREK4960K2UCAPSULE, LIQUID FILLED / ORAL4 mgExact identifier — unii candidate
24 equally ranked IID candidates
BUTYLATED HYDROXYTOLUENEBUTYLATED HYDROXYTOLUENE1P9D0Z171KTABLET, EXTENDED RELEASE / ORAL1 mgExact identifier — unii candidate
32 equally ranked IID candidates
LACTOSELACTOSEJ2B2A4N98GTABLET, DELAYED RELEASE / ORAL160 mgExact identifier — unii candidate
36 equally ranked IID candidates
CITRIC ACID MONOHYDRATECITRIC ACID MONOHYDRATE2968PHW8QPTABLET, CHEWABLE / ORAL7 mgExact identifier — unii candidate
88 equally ranked IID candidates
FD&C BLUE NO. 1FD&C BLUE NO. 1H3R47K3TBDSOLUTION / TOPICAL0.01 %w/wExact identifier — unii candidate
37 equally ranked IID candidates
SODIUM BENZOATESODIUM BENZOATEOJ245FE5EUINJECTION, SOLUTION / INTRAMUSCULAR4.8 %w/vExact identifier — unii candidate
35 equally ranked IID candidates
MAGNESIUM STEARATEMAGNESIUM STEARATE70097M6I30GRANULE / ORAL629 mgExact identifier — unii candidate
39 equally ranked IID candidates
CITRIC ACID MONOHYDRATECITRIC ACID MONOHYDRATE2968PHW8QPINJECTION, SOLUTION / INTRAMUSCULAR26 mgExact identifier — unii candidate
88 equally ranked IID candidates
SILICON DIOXIDESILICON DIOXIDEETJ7Z6XBU4CAPSULE, COATED / ORAL3 mgExact identifier — unii candidate
49 equally ranked IID candidates
SODIUM BENZOATESODIUM BENZOATEOJ245FE5EUTABLET / ORAL30 mgExact identifier — unii candidate
35 equally ranked IID candidates
SODIUM CHLORIDESODIUM CHLORIDE451W47IQ8XPOWDER, DENTIFRICE / DENTAL0.03 mg/mgExact identifier — unii candidate
134 equally ranked IID candidates
CELLULOSE, MICROCRYSTALLINEMICROCRYSTALLINE CELLULOSEOP1R32D61UTABLET / BUCCAL18 mgExact identifier — unii candidate
28 equally ranked IID candidates
CELLULOSE, MICROCRYSTALLINEMICROCRYSTALLINE CELLULOSEOP1R32D61UTABLET / ORAL6184 mgExact identifier — unii candidate
28 equally ranked IID candidates
SODIUM BENZOATESODIUM BENZOATEOJ245FE5EUSYSTEM / TOPICAL2 mgExact identifier — unii candidate
35 equally ranked IID candidates

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.